Clinical trials: Gout Disease
Gouty Arthritis (GA)
A Bioequivalence Study of Two Different Dosage Form of Genakumab
The purpose of this study is to investigate whether Genakumab Injection is bioequivalent to Genakumab for Injection.
- Trial name
- NCT06451848
- Testing
- Genakumab Injection (T, Solution for injection), Genakumab for Injection (R, Powder for solution for injection)
- Where
- China
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Gout
A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
This study will assess the serum uric acid lowering effects and safety of SHR4640 compared to placebo and Allopurinol in patients with gout
- Trial name
- NCT04052932
- Testing
- SHR4640 dose1, SHR4640 dose2, Allopurinol 300 MG
- Where
- China
- Volunteers
- 594 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gout
RDEA3170 and Febuxostat Combination Study in Gout Subjects
This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects and safety of RDEA3170 administered in combination with febuxostat compared to febuxostat administered alone in adult…
- Trial name
- NCT02246673
- Testing
- RDEA3170 15 mg, RDEA3170 10 mg, RDEA3170 2.5
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Ardea Biosciences, Inc.
Gout
Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares
The purpose of this study was to determine the safety and tolerability of rilonacept for participants with gout who were initiating allopurinol.
- Trial name
- UPSURGE (NCT01459796)
- Testing
- Rilonacept, Allopurinol
- Where
- 74 sites in United States
- Volunteers
- 220 people
- Sponsor
- Regeneron Pharmaceuticals
Gout Patients
Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients
The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in combination with febuxostat or allopurinol when administered to gout patients.
- Trial name
- NCT04155918
- Testing
- Group 1: AR882 Alone and in Combination with Febuxostat (FBX), Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)
- Where
- New Zealand
- Volunteers
- 30 people
- Sponsor
- Arthrosi Therapeutics
Gout
Extension Study of ABP-671 in Participants With Gout
The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the…
- Trial name
- NCT06276556
- Testing
- ABP-671, Allopurinol
- Where
- 54 sites in United States, Australia and 3 more
- Volunteers
- 43 people
- Sponsor
- Atom Therapeutics Co., Ltd
Gout
MPC-004 for the Treatment of an Acute Gout Flare
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-comparison to determine the efficacy and safety of a standard-dose of colchicine (4.8 mg) versus low-dose colchicine (1.8 mg) or…
- Trial name
- AGREE (NCT00506883)
- Testing
- High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose)
- Where
- 83 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Takeda
Gout, Hyperuricemia
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
- Conditions
- Gout, Hyperuricemia, Gout Flare, Tophi
- Trial name
- EURELIA1 (NCT05586958)
- Testing
- Tigulixostat
- Where
- 52 sites in United States, Georgia and 2 more
- Volunteers
- 354 people
- Sponsor
- LG Chem
Gout, Hyperuricemia
Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia
This is a randomized, double-blind, 3-period 3-treatment crossover followed by a 2-period 2-treatment crossover, phase 2 study in patients with documented hyperuricemia to evaluate the effect of tranilast on allopurinol…
- Trial name
- NCT01052987
- Testing
- Tranilast, Allopurinol, Combination - Tranilast and Allopurinol
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Nuon Therapeutics, Inc.
Gout
Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy Volunteers
This study was designed to compare and evaluate the pharmacokinetic characteristics of febuxostat after single oral administration of TMX-67 (test drug) and Feburic® tablet in healthy adults; and to evaluate safety and tolerance…
- Trial name
- NCT01563432
- Testing
- Feburic®, TMX-67
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Gout
Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
These are two replicate studies to evaluate the safety and efficacy of PEG (polyethylene glycol)-uricase in controlling the uric acid level in symptomatic gout patients with high uric acid levels who are unable to take standard…
- Trial name
- NCT00325195
- Testing
- pegloticase
- Where
- 56 sites in United States, Canada and 1 more
- Volunteers
- 225 people
- Sponsor
- Savient Pharmaceuticals
Chronic Gout Refractory to Conventional Therapy
Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients
The purpose of the study is to evaluate the safety and clinical effect of re-exposure to a 24 week course of treatment of pegloticase i.v. in subjects whose last exposure to pegloticase i.v.
- Trial name
- NCT00675103
- Testing
- pegloticase 8 mg i.v.
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Savient Pharmaceuticals
Gout
Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects
This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects of RDEA3170 administered in combination with allopurinol compared with allopurinol administered alone in adult subjects with…
- Trial name
- NCT02498652
- Testing
- RDEA3170 2.5 mg, allopurinol 300 mg
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- Ardea Biosciences, Inc.
Soft Tissue Injuries, Gouty Arthritis
AMPED Outcomes Registry of Post-ED Pain Management
Study aims to assess patient-recorded outcomes of pain control medications prescribed in the ER after visits for specific painful injuries/illnesses.
- Conditions
- Soft Tissue Injuries, Gouty Arthritis, Fractures, Ureteral Colic
- Trial name
- AMPED (NCT01626235)
- Where
- 11 sites in United States
- Volunteers
- 843 people
- Sponsor
- Radnor Registry Research, Inc
Gout
Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.
The purpose of this study is to compare febuxostat, allopurinol and placebo, once daily (QD), in subjects with gout.
- Trial name
- APEX (NCT00174915)
- Testing
- Febuxostat, Allopurinol
- Volunteers
- 1,072 people
- Sponsor
- Takeda
Gout
A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients
A phase 3 clinical trial to compare and evaluate efficacy and safety of epaminurad with febuxostat in gout patients.
- Trial name
- EPIC (NCT05815901)
- Testing
- Epaminurad 6 mg, Epaminurad 9 mg, Febuxostat 40 mg
- Where
- South Korea
- Volunteers
- 612 people
- Sponsor
- JW Pharmaceutical
Gout Chronic, Gout
Drug-Drug Interaction Study of ABP-671 in Gout Patients
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients.
- Conditions
- Gout Chronic, Gout, DDI (Drug-Drug Interaction)
- Trial name
- NCT07367971
- Testing
- ABP-671 plus allopurinol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Atom Therapeutics Co., Ltd
Osteoarthritis, Rheumatoid Arthritis
Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)
This postmarketing study was conducted to describe prescribing patterns for etoricoxib (ARCOXIA®) in General Practice and describe the incidence of selected adverse events recorded in the United Kingdom (UK) Medicines and Health…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Gout
- Trial name
- NCT01685424
- Testing
- Etoricoxib
- Volunteers
- 79,189 people
- Sponsor
- Organon and Co
Gout
A Study of Dotinurad Versus Allopurinol in Participants With Gout
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.
- Trial name
- NCT07089875
- Testing
- Allopurinol, Dotinurad
- Where
- 119 sites in United States, Poland and 1 more
- Volunteers
- 500 people
- Sponsor
- Crystalys Therapeutics
Acute Gout Flare, Gout Attack
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
- Conditions
- Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis
- Trial name
- NCT05658575
- Testing
- Dapansutrile
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 300 people
- Sponsor
- Olatec Therapeutics, Inc.